secwatch.observer — SEC 8-K summary
======================================

Issuer:     Maze Therapeutics, Inc. (MAZE)
CIK:        0001842295
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0001193125-26-122774
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maze Q4 net loss $34.6M; MZE829 Phase 2 35.6% uACR drop; Neil Kumar joins board
-------------------------------------------------------------------------------

- Net loss $34.6M in Q4, $131.1M for FY2025; cash $360M provides runway into 2028.
- MZE829 Phase 2 HORIZON: mean uACR reduction 35.6% at week 12; 50% patients >30% reduction.
- FSGS subgroup 61.8% mean uACR reduction; non-diabetic AMKD 48.6%; well-tolerated, no serious AEs.
- Neil Kumar (BridgeBio CEO) appointed to board effective March 27, 2026; receives option grant.
- Plans to advance MZE829 to pivotal program; MZE782 Phase 2 trials in PKU and CKD expected in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842295/000119312526122774/0001193125-26-122774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842295/000119312526122774/maze-20260324.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-122774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer